Clinical characteristics in patients with SARS-CoV-2/HBV co-infection
Clinical characteristics in patients with SARS-CoV-2/HBV co-infection
复制标题
DOI：
10.1111/jvh.13362
复制
发表时间：
2020-08-16
影响因子：
2.5
通讯作者：
Cheng, Jilin
中科院分区：
文献类型：
--
作者：
Chen, Liping;Huang, Shaoping;Cheng, Jilin
新冠肺炎已经成为一场全球性的流行病，并引起了国际社会的关注。虽然新冠肺炎相关性肝损伤的临床特征已有研究，但尚未见有关新冠肺炎合并乙肝病毒感染者的临床特征的报道和研究。本研究旨在评估SARS-CoV-2/乙肝病毒混合感染是否会影响肝功能和疾病转归。本研究纳入2020年1月20日至2020年2月24日在上海市公共卫生临床中心(新冠肺炎上海定点医院)确诊的326例新冠肺炎患者，并进行随访至2月29日。对患者的临床、实验室资料及住院时间进行回顾性分析。合并乙肝病毒感染者20例(6.1%)与未感染者306例(93.9%)肝功能指标无明显差异。但与HBs Ag阳性组[145.4 mg/L(103.9~179.2)]相比，HBs Ag阳性组前白蛋白水平较低[102.3 mg/L(76.22~160.2)，P=0.0367]。两组患者的出院率和住院时间也无明显差异。综上所述，我们没有发现SARS-CoV-2/乙肝病毒混合感染会加重肝脏损伤或延长住院时间的证据。
COVID-19 has become a global pandemic and garnered international attention. Although the clinical features of COVID-19-related liver injury have been investigated, there have been no reports and studies on the clinical characteristics of COVID-19 patients co-infected with hepatitis B virus (HBV). This study aimed to evaluate whether SARS-CoV-2/HBV co-infection could influence liver function and the disease outcome. All 326 confirmed COVID-19 cases in Shanghai Public Health Clinical Center (The COVID-19 designated hospital in Shanghai, China) from 20 January 2020 to 24 February 2020 were enrolled and followed up until February 29 in this study. The clinical, laboratory data and the length of stay were collected and analysed retrospectively. 20 patients with HBV co-infection (6.1%) and 306 patients (93.9%) without HBV infection showed no differences in the level of liver function parameters. However, compared with HBsAg- patients [145.4 mg/L (103.9-179.2)], HBsAg + patients had a lower level of prealbumin [(102.3 mg/L (76.22-160.2),P = .0367]. There were also no significant differences for the discharge rate and the length of stay between two groups. Taken together, we found no evidence that SARS-CoV-2/HBV co-infection could aggravate liver injury or extend duration of hospitalization.